Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FIB918
- Development stage
- Preclinical
- Lead developer
- Fibrocor Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Parenteral
01
Overview
FIB918 is a monoclonal antibody in preclinical development for the treatment of hereditary nephritis (specifically Alport Syndrome), a rare genetic kidney disease characterized by severe renal fibrosis. The drug is being developed to modulate key molecular pathways in fibrosis, aiming to deliver a significant advancement over current limited treatment options for Alport Syndrome. Mechanistically, FIB918 targets discoidin domain receptors (DDR modulation) and integrins to impact fibrotic processes in kidney tissue. Developed by Fibrocor Therapeutics, FIB918 is intended for parenteral use and has not received orphan drug designation at present. Phase 1 clinical trials are planned to begin in late 2025 as part of a strategic collaboration with McQuade Center for Strategic Research and Development (MSRD)[1][2][4][7][13].
- Brand names
- FIB918FIB-918FIB 918
- Other names
- FIB918FIB-918FIB 918
02
Targets
NeuraminidaseDDR1 (Discoidin domain receptor 1)
Beyond the preview
Go deeper on FIB918.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FIB918.